Department of Neurosciences Ophthalmology and Genetics, University of Genoa, Italy.
Curr Opin Immunol. 2010 Dec;22(6):768-74. doi: 10.1016/j.coi.2010.10.012. Epub 2010 Nov 17.
The adult stem/progenitor cells from bone marrow and other tissues referred to as mesenchymal stem cells or multipotent mesenchymal stromal cells (MSCs) display a significant therapeutic plasticity as reflected by their ability to enhance tissue repair and influence the immune response both in vitro and in vivo. In this review we will focus on the paradigmatic preclinical experience achieved testing MSCs in experimental autoimmune encephalomyelitis (EAE), a model for multiple sclerosis. We will emphasize how the paradigm changed over time from the original prediction that MSCs would enhance tissue repair through their transdifferentiation into somatic cells to the current paradigm that they can produce therapeutic benefits without engraftment into the injured tissues. The data will be reviewed in terms of the potentials of MSCs for therapy of autoimmune diseases.
骨髓和其他组织中的成体干细胞/祖细胞被称为间充质干细胞或多能间充质基质细胞（MSCs），它们在体外和体内都表现出显著的治疗可塑性，这反映在它们增强组织修复和影响免疫反应的能力上。在这篇综述中，我们将重点介绍在实验性自身免疫性脑脊髓炎（EAE）模型中测试 MSCs 的典范临床前经验，EAE 是多发性硬化症的模型。我们将强调随着时间的推移，这一范式是如何从 MSCs 通过转分化为体细胞来增强组织修复的原始预测转变为当前的范式，即它们可以在不植入受损组织的情况下产生治疗益处。这些数据将根据 MSCs 治疗自身免疫性疾病的潜力进行审查。
